BioSource Awarded Patent for Probe Technology.CAMARILLO, Calif. -- BioSource International, Inc. today announced that it was issued U.S. Patent No. 6,818,420, "Methods of Using Fluorescent Energy Transfer (FET FET: see transistor. (Field Effect Transistor) One of two major categories of transistor; the other is bipolar. FETs use a gate element that, when charged, creates an electromagnetic field that changes the conductivity of a silicon ) Labeled Oligonucleotides that includes a 3'-5' Exonuclease exonuclease /exo·nu·cle·ase/ (ek?so-noo´kle-as) any nuclease specifically catalyzing the hydrolysis of terminal bonds of deoxyribonucleotide or ribonucleotide chains, releasing mononucleotides. Resistant Quencher quench tr.v. quenched, quench·ing, quench·es 1. To put out (a fire, for example); extinguish. 2. To suppress; squelch: Domain and Compositions for Practicing the Same," by the U.S. Patent and Trademark Office. The methods and compositions claimed in this patent are useful in molecular diagnostics such as molecular techniques that employ a primer extension Primer extension is a technique whereby the 5' ends of RNA or DNA can be sequenced. In this technique, we need an oligonucleotide from a transcribed DNA sequence. This oligonucleotide is annealed to the mRNA. reaction in the presence of a polymerase having 3'-5' exonuclease activity and at least one FET-labeled oligonucleotide probe that includes a 3'-5' exonuclease resistant quencher domain. The technology covered by the patent is particularly suited for use in high fidelity PCR-based reactions, including Single Nucleotide Polymorphism Noun 1. single nucleotide polymorphism - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily successful enough to recur in a (SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily ) detection and allelic al·lele n. One member of a pair or series of genes that occupy a specific position on a specific chromosome. [German Allel, short for Allelomorph, allelomorph, from English variation detection applications, as it enhances the accuracy of SNP detection and allele allele (əlēl`): see genetics. allele Any one of two or more alternative forms of a gene that may occur alternatively at a given site on a chromosome. discrimination. "This new patent is a significant addition to our intellectual property portfolio for biological assay systems," noted Kevin Reagan, Ph.D., BioSource's Executive Vice-President of Technical Operations. "The methods and compositions covered are important to the emerging field of pharmacogenomics, where the specificity of results, including in SNP detection, is critical to the proper interpretation of the assay." About BioSource International, Inc. BioSource International, Inc. is a broad-based life sciences company focused on providing integrated solutions in the areas of functional genomics, proteomics, and drug discovery through the development, manufacturing, marketing, and distribution of unique, biologically active reagent systems which facilitate, enable, and accelerate pharmaceutical development and biomedical research. For more information, please visit the Company's Web site at www.biosource.com. Statements included in this release that are not historical facts may be considered forward-looking statements that are subject to a variety of risks and uncertainties. In addition, readers are urged to consider statements that include the terms "believes," "belief," "expects," "plans," "objectives," "anticipates," "intends," "targets," "projections," or the like to be uncertain and forward looking. For these statements, we claim the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Factors that could cause actual results to differ and vary materially from expectations include, but are not limited to, our ability to expand our product offerings and any transition to new products, product quality and availability, any change in business conditions, changes in our sales strategy and product development plans, competitive pricing pressures, continued market acceptance of our products, name recognition of our products, delays in the development of new technology, possible invalidity or infringement issues related to intellectual property or proprietary rights, changes in customer buying patterns, one-time events, and other important factors disclosed previously and from time to time in our filings with the Securities and Exchange Commission. These factors should not be construed as exhaustive or as any admission regarding the adequacy of disclosures made by us. We cannot always predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion